Table of Content

25 August 2023, Volume 15 Issue 4 Previous Issue    Next Issue

Select

Comprehensive diagnosis and treatment of precision surgery for colorectal cancer  LIAO Leen, PAN Zhizhong 2023, 15 (4):  361-369.  doi: 10.3969/j.issn.1674-5671.2023.04.01 Abstract ( 1421 )   PDF   Save Related Articles | Metrics

Select

Progress of immunotherapy 3.0 in advanced biliary tract cancer  ZHANG Ting, ZHAO Haitao 2023, 15 (4):  370-374.  doi: 10.3969/j.issn.1674-5671.2023.04.02 Abstract ( 293 )   PDF   Save Related Articles | Metrics

Select

Recent advances in diagnosis and treatment of renal cell carcinoma  ZANG Xinyi, ZHENG Junhua, ZHAI Wei 2023, 15 (4):  375-382.  doi: 10.3969/j.issn.1674-5671.2023.04.03 Abstract ( 313 )   PDF   Save Related Articles | Metrics

Select

Prognostic value of ADH1B in patients with hepatocellular carcinoma with vascular invasion and its effect on the biological behavior of liver cancer QIN Shuiling, XU Jingxuan, WEI Haowen, MA Liang, QI Lunan 2023, 15 (4):  383-390.  doi: 10.3969/j.issn.1674-5671.2023.04.04 Abstract ( 233 )   PDF   Save Objective To investigate the clinical value of alcohol dehydrogenase 1B (ADH1B)in patients with hepatocellular carcinoma with vascular invasion (VI⁃HCC) and its effect on the biological function of liver cancer cells. Methods RNA sequencing of VI⁃HCC tissues, and GO, KEGG, GSEA, WGCNA analysis were performed. The expression level of ADH1B protein in tissues was detected by immunohistochemistry. The Kaplan⁃Meier method was used to draw the survival curve and the log⁃rank test was performed to analyze the survival difference of patients with different ADH1B protein expression groups. Univariate and multivariate Cox regression models were used to analyze the independent risk factors affecting the prognosis of patients with VI⁃HCC after surgery, and Spearman test was used to analyze the correlation between ADH1B and AFP/Ki67. The lentivirus overexpressing ADH1B and its negative control were used to infect the Huh7 cells to construct a stable ADH1B overexpression strain. The expression level of ADH1B mRNA in cells were detected by qRT⁃PCR. EDU and plate cloning assay were used to detect the proliferation ability of the cells. Transwell invasion and migration assay and scratch assay were used to detect the invasion and migration ability of the cells. Flow cytometry was used to detect apoptosis of cells. Results The results of RNA sequencing showed that the primary tumors of VI⁃HCC patients with poor prognosis after radical resection was characterized by metabolic reprogramming. The results of immunohistochemistry showed that the expression level of ADH1B protein in VI⁃HCC tissues was significantly lower than that in adjacent normal tissues (P<0.001). The expression of ADH1B protein in patients with good prognosis was significantly higher than that in patients with poor prognosis (P<0.05). Low expression of ADH1B could reduce both the relapse⁃free survival (RFS) and the overall survival (OS) of patients (all P<0.01). The expression level of ADH1B was negatively correlated with AFP and Ki67 levels (all P<0.01). Cox regression model showed that low expression level of ADH1B was an independent risk factor for postoperative RFS and OS in the patients with VI⁃HCC. Cytological results showed that overexpression of ADH1B could inhibit the proliferation, invasion and migration of cells, and promoted the apoptosis (all P<0.05). Conclusions The expression of liver metabolism⁃detoxification gene ADH1B is down⁃regulated in HCC, and its low expression reduces the RFS and OS in patients with VI⁃HCC. The possible mechanism is that ADH1B inhibits the proliferation, invasion and migration of HCC cells, and promotes the apoptosis of HCC cells. Related Articles | Metrics

Select

Clinical analysis of rituximab-induced interstitial lung disease in newly treated patients with diffuse large B-cell lymphoma: A retrospective study of single-center GUO Jia, WANG Chengji, LIANG Yuanzheng, WANG Liang 2023, 15 (4):  391-397.  doi: 10.3969/j.issn.1674-5671.2023.04.05 Abstract ( 180 )   PDF   Save Objective To investigate the incidence of rituximab⁃induced interstitial lung disease (RILD) in newly treated patients with diffuse large B⁃cell lymphoma (DLBCL) and its correlation with clinicopathological features. Methods The clinicopathological data of 110 patients with DLBCL who were treated in the Department of Hematology of Beijing Tongren Hospital from January 2020 to December 2022 were retrospectively collected. All patients received rituximab⁃ containing first⁃line treatment regimen, and the specific regimen was adjusted on an individual basis, with one cycle every 21 days. The occurrence of RILD was assessed by chest CT or PET⁃CT examinations after the completion of the 2nd and 4th cycles of chemotherapy, and the 8th cycle of rituximab treatment, respectively. The risk factors of RILD were assessed by chi⁃square test and multivariate Logistic regression analysis to construct risk prediction model, and a nomogram model was constructed to predict the occurrence rate of RILD. Results The terminal complete remission rate of 110 DLBCL patients was 84.2% after treatment. Twenty⁃one patients (19.1%) developed RILD during treatment, and the median time of occurrence was the 4th cycle of first⁃line treatment(range: 2~8 cycles). The median duration of treatment for RILD was 10 days (range: 5~60 days). Except for 5 patients with no obvious symptoms or mild symptoms, 16 patients with moderate and severe symptoms received glucocorticoid⁃containing regimens, and the situations of all the patients improved after treatment. The incidence of RILD in the patients who received pegylated liposomal doxorubicin (PLD) regimens was significantly higher than those treated with pirarubicin regimens (29.7% vs 13.7%,P=0.043). The patients who smoked (25.9% vs 16.9%, P=0.298) and were more than 60 years old (23.2% vs 12.2%, P=0.156) also had a higher incidence of RILD, but the difference was not statistically significant. The RILD risk prediction model was constructed according to the risk factors, and the patients were divided into the high⁃risk group and low⁃risk group, and the incidence of RILD was significantly different between the two groups (P=0.027). The results of nomogram model analysis showed that the incidence of RILD was above 35% in patients ≥60 years old with a history of smoking who used PLD. Conclusion The patients with DLBCL should be alert to the occurrence of RILD after using rituximab⁃containing chemotherapy, especially in smoking and elderly patients. The prevention and monitoring of RILD should be strengthened after using PLD.  Related Articles | Metrics

Select

Construction and validation of a prognostic model for cervical cancer based on tumor immune cycle-related genes HUANG Chuntao, WEN Tianbin, LYU Sihui, LIANG Jinlan, WANG Qi 2023, 15 (4):  398-405.  doi: 0.3969/j.issn.1674-5671.2023.04.06 Abstract ( 144 )   PDF   Save Objective To construct a prognostic model for cervical cancer based on tumor immune cycle related⁃genes (TICRGs), and to detect the expression of modeling factors in clinical tissue samples to verify the efficacy of the model. Methods The transcriptome profile of cervical cancer samples in TCGA database was used as the training set, and the cervical cancer genes expression profile GSE44001 in the GEO database was used as the validation set. The transcriptome data of tumor samples and normal cervical tissues were compared and analyzed to obtain cervical cancer TICRGs. The prognostic TICRGs were screened by the univariable Cox regression, and the prognostic model of cervical cancer was constructed by LASSO⁃Cox analysis method. The area under the curve (AUC) of receiver operating characteristic (ROC) curve and concordance index (C⁃index) were used to evaluate the model. GSE44001 data set was used to externally verify the model, and the feasibility of the model was verified by the multi⁃color fluorescence immunohistochemistry experiment. Results A cervical cancer prognosis model consisting of CCL17, CXCL3 and VTCN1 was constructed in this study. Prognostic survival analysis showed a significant difference in prognosis between the high⁃risk and low⁃risk groups (P<0.001). The ROC curve and the C⁃index indicated that the model showed moderate prognostic efficacy. Multivariable Cox regression showed that risk score was an independent prognostic factor for cervical cancer patients ( P=0.010). Immunoinfiltration analysis revealed that CD8+T cells was a protective factor for the prognosis of cervical cancer(P=0.017). The results of the multi⁃color fluorescence immunohistochemistry experiment were consistent with the results of the prognostic model. Conclusions The prognostic model constructed based on tumor immune cycle⁃related genes CCL17, CXCL3 and VTCN1 has moderate predictive efficacy in predicting the prognosis of patients with cervical cancer.  Related Articles | Metrics

Select

Rare histological features of giant cell tumor of bone with pseudosarcomatous changes and high mitotic activity after Denosumab treatment SHEN Yan, YANG Tong, CHEN Guidong, GU Wanyi 2023, 15 (4):  406-410.  doi: 10.3969/j.issn.1674-5671.2023.04.07 Abstract ( 135 )   PDF   Save Objective To investigate the histological features, diagnosis and differential diagnosis of giant cell tumor of bone (GCTB) with pseudosarcomatous changes and high mitotic activity after Denosumab treatment. Methods The clinical data, radiologic and pathological features of a patient with GCTB treated with Denosumab for 3 weeks prior to surgery in the Second Affiliated Hospital of Guangzhou Medical University was retrospectively analyzed, and the relevant literature was reviewed. Results A 39⁃year⁃old male patient presented with swelling and pain right knee joint and walking limitation as the main clinical symptom. The X⁃ray result showed an expansive, osteolytic lesion in the subarticular medullary cavity of the right distal femur. Th initial biopsy before Denosumab treatment showed typical features of GCTB. After 3 weeks of Denosumab treatment, curettage was performed. Histological findings showed that giant cells almost completely disappeared, and the tumor was mainly composed of spindle mononuclear cells with moderate to high density, accompanied by high mitotic activity, focal necrosis and immature new bone formation, forming a osteosarcoma⁃like morphology. No recurrence was found in 9 months follow⁃up. Conclusions The pseudosarcomatous change with high mitotic activity is a rare histological phenotype of GCTB after Denosumab treatment, which is easily misdiagnosed as the true sarcoma or malignant transformation of GCTB. Paying attention to clinical treatment history and being familiar with the histological features are essential for accurate diagnosis and avoiding misdiagnosis. Related Articles | Metrics

Select

Expression of programmed death-ligand 1 and cancer-associated fibroblasts in breast cancer tissues and its clinical significance ZHU Yongqi, ZHU Yan, SHENG Meihong, ZHANG Xiaojuan, LIU Hongbin, LI Li 2023, 15 (4):  411-416.  doi: 10.3969/j.issn.1674-5671.2023.04.08 Abstract ( 152 )   PDF   Save Objective To investigate the expression and clinical value of cancer⁃associated fibroblasts (CAFs) and programmed death⁃ligand 1 (PD⁃L1) in breast invasive ductal carcinoma. Methods A total of 121 surgical specimens of breast invasive ductal carcinoma were collected in the Second Affiliated Hospital of Nantong University who underwent modified radical mastectomy, from January 2019 to June 2021. The expression of CAFs and PD⁃L1 in breast cancer tissues were detected by using immunohistochemical staining, and the correlation of CAFs and PD⁃L1 with clinicopathological features was analyzed. Spearman correlation analysis was used to analyze the correlation between the expression of CAFs and PD⁃L1. The factors affecting the progression⁃free survival (PFS) were analyzed based on univariate and multivariate Cox analyses. Kaplan⁃Meier method was used to draw the survival curve and Log⁃rank test was used to compare the survival difference. Results CAFs was highly expressed in breast cancer tissues and were significantly correlated with tumor size, lymph node metastasis and TNM stage (all P<0.01). PD⁃L1 was highly expressed in breast cancer tissues, and was significantly correlated with lymph node metastasis, TNM stage and estrogen receptor (ER) expression(all P<0.01). The positive expression of CAFs was positively correlated with that of PD⁃L1 in breast cancer tissues (r=0.265, P=0.011). Univariate Cox analysis showed that histological grade, lymph node metastasis, TNM stage, ER positive expression and PD⁃L1 expression were all correlated with the prognosis of breast cancer (all P<0.05). Multivariate Cox analysis showed that positive PD⁃L1 expression was an independent risk factor for poor PFS (P<0.05). Survival analysis showed that there were statistically significant differences in 1⁃year PFS rate (100.00% vs 84.09%;  χ2= 11.115, P=0.001) and 3⁃year PFS rate (95.92% vs 79.55%; χ2=6.312, P=0.012) between the PD⁃L1 negative expression group and the PD⁃L1 positive expression group.   Conclusions CAFs and PD⁃L1 are highly expressed in breast cancer tissues, and PD⁃L1 is associated with poor prognosis. There may exist interplay between CAFs and PD⁃L1 in promoting the malignant progression of breast cancer, which is expected to become a new target for the immunotherapy of breast cancer. Related Articles | Metrics

Select

Prediction of radiosensitivity in locally advanced cervical cancer based on 18F-FDG PET/CT radiomics model CHEN Xiaoxia, LAN Ying, WU Nengxian, SONG Honglin 2023, 15 (4):  417-422.  doi: 0.3969/j.issn.1674-5671.2023.04.09 Abstract ( 103 )   PDF   Save Objective  To construct a radiomics model based on 18F⁃FDG PET/CT images, and analyze its efficacy in predicting radiotherapy sensitivity of locally advanced cervical cancer (LACC). Methods The clinical data of cervical cancer patients who underwent radical radiotherapy in the Department of Gynecologic, Guangxi Medical University Cancer Hospital from January 2018 to December 2022 were collected and randomly divided into a training set (169 patients) and a test set (43 patients) in a ratio of 8∶2. Pre⁃treatment  18F⁃FDG PET/CT images of patients were collected, the areas of interest were manually delineated and the radiomics features were extracted. The features were regularized and screened by the intra⁃group correlation coefficient, Pearson correlation analysis and the least absolute shrinkage and the selection operator regression. The radiomics features and their weighting efficients obtained and Radscore values were calculated for each patient. The differences in Radscore between radiosensitive and radioresistant groups were compared. The Logistic regression machine learning model for PET, CT and combined PE/CT were constructed, respectively, and the model efficacy was evaluated based on the receive operating characteristic curve (ROC), calibration curve, and decision curve analysis. Results A total of 212 LACC patients were included in this study, and the Radscores of the radioresistant group were significantly higher than those of the radiosensitive group, with a statistically significant difference (P<0.001). In both the training and test sets, the area under the ROC curve of the combined PET/CT model was 0.900 (95%CI: 0.832-0.968) and 0.754 (95%CI: 0.569-0.939), respectively, and the predictive efficiency of the combined PET/CT model was better than that of the individual PET or CT model. The DCA curve showed that the PET/CT⁃based radiomics models showed significant intervention benefits and had better clinical benefits in predicting LACC sensitivity before radiotherapy compared to those without the prediction model. The calibration curve showed that the predicted values of the three models were in good agreement with the observed values. Conclusions The PET/CT⁃based radiomics models has a good predictive value for the sensitivity of LACC to radiotherapy. Related Articles | Metrics

Select

Research progress on the pathogenesis of anorexia of cancer HUANG Lei, JIN Chunhui 2023, 15 (4):  423-428.  doi: 10.3969/j.issn.1674-5671.2023.04.10 Abstract ( 246 )   PDF   Save Related Articles | Metrics

Select

Research progress of the diagnosis and treatment of multiple glioblastoma XU Hao, YU Shengnan, REN Qinglan 2023, 15 (4):  429-434.  doi: 10.3969/j.issn.1674-5671.2023.04.11 Abstract ( 223 )   PDF   Save Related Articles | Metrics

Select

Research progress of neoadjuvant drug therapy for non-small cell lung cancer ZHONG Guohui, LIANG Ningsheng, JIANG Neng 2023, 15 (4):  435-443.  doi: 10.3969/j.issn.1674?5671.2023.04.12 Abstract ( 140 )   PDF   Save Related Articles | Metrics

Select

Research progress on the inducement and prognostic factors of secondary primary breast cancer in tumor patients LIU Guohui, WANG Jingxuan 2023, 15 (4):  444-448.  Abstract ( 153 )   PDF   Save Related Articles | Metrics

Select

Research progress of m6A modification in the occurrence and development of hepatocellular carcinoma LUO Tai, HUANG Qiongguang, LU Zhan, YU Hongping, GONG Wenfeng 2023, 15 (4):  449-455.  doi: 10.3969/j.issn.1674-5671.2023.04.14 Abstract ( 171 )   PDF   Save Related Articles | Metrics

Select

Research progress of variable splicing in tumor angiogenesis and tumor therapy CHEN Na, LIAO Dezhong, LI Chao, MA Hong 2023, 15 (4):  456-460.  doi: 10.3969/j.issn.1674-5671.2023.04.15 Abstract ( 231 )   PDF   Save Related Articles | Metrics

Select

Whole organ inversion complicated with pancreatic cancer: a case report ZHU Zemin, YAO Yi, XU Tao, XIE Xiaochun, TANG Caixi, ZHAO Zhijian 2023, 15 (4):  461-462.  doi: 10.3969/j.issn.1674-5671.2023.04.16 Abstract ( 134 )   PDF   Save Related Articles | Metrics